A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-playing the approval of blood cancer drug Breyanzi to avoid paying out a more than $6 billion contingent value right.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
